Patents by Inventor Yun-Xing Cheng

Yun-Xing Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic compounds, compositions and methods of use thereof
    Patent number: 11731943
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: August 22, 2023
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230242530
    Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: April 7, 2023
    Publication date: August 3, 2023
    Applicant: Genentech, Inc.
    Inventors: Simon Charles GOODACRE, Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Limin CHENG, Rongbao HUA
  • PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
    Publication number: 20230206644
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, Paul GIBBONS, Yun-Xing CHENG, Simon Charles GOODACRE
  • TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF
    Publication number: 20230167123
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: December 8, 2022
    Publication date: June 1, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • CYCLIC PEPTIDE ANTIBIOTICS
    Publication number: 20230025834
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 26, 2023
    Applicant: Genentech, Inc.
    Inventors: Guosheng WU, Emily J. HANAN, Marie-Gabrielle BRAUN, Sharada S. LABADIE, Keira GARLAND, Richard M. PASTOR, Paul Anthony GIBBONS, Yuhong FU, Yun-Xing CHENG
  • INHALABLE DRY POWDER AND AEROSOL FORMULATIONS OF JAK INHIBITORS
    Publication number: 20230016791
    Abstract: wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 19, 2023
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Marie Grandner, Daniel G.M. Shore, Marian C. Bryan
  • Pyrazolopyrimidine inhibitors of JAK kinases and uses thereof
    Patent number: 11453671
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 27, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G. M. Shore, Marian C. Bryan
  • TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20220281893
    Abstract: Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Matthew Leo LANDRY, Sushant MALHOTRA, Michael SIU, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE
  • INHALED POWDER FORMULATIONS
    Publication number: 20220204517
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 30, 2022
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • PYRAZOLOPYRIMIDINE ARYL ETHER INHIBITORS OF JAK KINASES AND USES THEREOF
    Publication number: 20220106322
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Wei Li, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20220024945
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 27, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Wei LI
  • Pyrazolopyrimidine compounds and methods of use thereof
    Patent number: 11155557
    Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: F. Anthony Romero, Mark Zak, Guiling Zhao, Paul Gibbons, Wei Li, Yun-Xing Cheng, Po-Wai Yuen, Limin Cheng
  • THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210179564
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 17, 2021
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF
    Publication number: 20200399275
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, Marian C. Bryan
  • TETRAZOLE-SUBSTITUTED PYRAZOLOPYRIMIDINE INHIBITORS OF JAK KINASES AND USES THEREOF
    Publication number: 20200399274
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 24, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Naomi S. Rajapaksa, Yun-Xing Cheng, Jessica Grandner, Daniel G.M. Shore, F. Anthony Romero, Marian C. Bryan
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20200352951
    Abstract: Methods of using compounds and salts thereof as JAK kinase inhibitors are described herein, including methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: July 28, 2020
    Publication date: November 12, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG
  • PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
    Publication number: 20200339604
    Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: July 13, 2020
    Publication date: October 29, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, Paul GIBBONS, Yun-Xing CHENG, Simon Charles GOODACRE
  • 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200270248
    Abstract: Compounds of Formula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Simon Charles GOODACRE, Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Limin CHENG, Rongbao HUA
  • INHALED POWDER FORMULATIONS
    Publication number: 20200165260
    Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: Genentech, Inc.
    Inventors: Yun-Xing Cheng, Paul Gibbons, Terry Kellar, Wei Li, Rohan Mendonca, Po-wai Yuen, Mark Edward Zak, Lei Zhang
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20200062779
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Wei LI